Treace Medical - FloodGate Medical

Experience the Future of Bunion Surgery

About Us

Treace Medical Concepts, Inc. is a medical technology company focused on improving surgical care for bunions and related midfoot deformities. Bunions affect around 67 million Americans, with 1.1 million considered annual surgical candidates. Treace developed the patented Lapiplasty® 3D Bunion Correction® System, which corrects bunions in all three dimensions and stabilizes the root cause—the unstable joint. The company also offers the Adductoplasty® Midfoot Correction System and the Hammertoe PEEK Fixation System, expanding its solutions for foot deformities. Treace continues to grow in the foot and ankle market with its versatile SpeedPlate™ Rapid Compression Implants.

Look at the Leaders of Treace Medical

John T. Treace

CEO, Founder, and Board Member

Guy Guglielmino

Chief Commercial Officer

Daniel Owens

Chief Human Resources Officer

Featured Services and Innovations

Lapiplasty®

Bunions are complex, 3D deformities caused by an unstable joint in the middle of the foot that allows your bone to drift out of alignment.

Advanced surgical technology returns your entire bone to normal 3D alignment and the unstable joint is secured with patented, titanium plates to get back on your feet in <2 weeks (in a walking boot).

Adductoplasty®

MTA is a common foot deformity that causes the front half of the foot, or forefoot, to turn inward. A full correction of the bunion may require repositioning the bones of the 2nd and 3rd toes in order to make room for complete first toe realignment.

The Adductoplasty® Procedure corrects the alignment of the second and third toes, creating the necessary space to perform the Lapiplasty® Procedure and bring the big toe back into normal alignment.

SpeedMTP

Fast. Sleek. Secure.

SpeedMTP™ is an ultra-low profile dorsal MTP implant, combining SpeedPlate™ and FastPitch® technologies for fast insertion, robust strength, and dynamic compression.

Nanoplasty 3D MIS Bunion Correction

Elegant. Advanced. MIS.

The Nanoplasty™ procedure is designed to deliver a reproducible 3D correction of the bunion deformity through a cosmetically appealing, hidden incision on the side of the foot.

Real People, Real Stories

Thomas

I think I was most surprised that I was able to walk so soon and put pressure on my foot again without much pain.

Lauren

Being able to wear heels or really any shoe for longer than an hour…has made a world of difference.

Emily

It’s so nice to be able to do everything I want to do – without pain!

News and Stories

Treace Announces Upcoming Board Chair Transition

PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace will succeed James T. Treace, who notified the Board that he will retire from the Board when his current term as a director ends at the 2025 Annual Meeting of Stockholders, which is expected to occur on May 20, 2025. John T. Treace will continue to serve as Chief Executive Officer and will assume the role of Chairman of the Board immediately following the 2025 Annual Meeting of Stockholders. Richard W. Mott will continue to serve as the lead independent director.

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® clinical study, at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona.

Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Phoenix, Arizona from March 27-30, 2025.

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!